

**Session A: "Capitalizing on Europe's research potential:
three generations of entrepreneurs"**

SPEAKER PROFILE: Alexander VON GABAIN, Co-founder, CSO and Member of the Management Board, Intercell AG; Member of EIT Governing Board.



He obtained his Ph.D. in Genetics at the University of Heidelberg and held a post-doctorate position at the Stanford University. In the 1980s and 1990s he was a Professor at the University of Umeå and at the Karolinska Institutet, Sweden, as well as advisor to pharmaceutical and biotech companies. During 1992-1998 he was Chair of Microbiology at the University of Vienna at the Campus Vienna Biocenter, Austria. In 1998, he co-founded Intercell AG and led the company as CEO, until it was floated on the Vienna Stock Market in 2005.

He holds a professorship of Microbiology at the Max Perutz Laboratories, Vienna, and a foreign adjunct professorship at the Karolinska Institutet in Stockholm. He is member of several professional organizations and serves in the Boards of biotech enterprises, including TVM Capital in Munich. He is also a member of the WHO Committee "Stop TB". Recently, he has been appointed into the founding Supervisory Board of the European Institute of Innovation and Technology.

COMPANY PROFILE: Intercell AG

Intercell AG is an innovative biotechnology company that develops novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical needs.

Intercell is today an innovative franchise within the travelers' vaccine market, including a vaccine to prevent Japanese Encephalitis – the Company's first product on the market, and a Travelers' Diarrhea vaccine patch about to enter Phase III clinical trials. Furthermore, Intercell is considered a leader within hospital-acquired infections with a Pseudomonas vaccine produced in-house (Phase II) and a partnered Staphylococcus aureus vaccine (Phase II/III, sequential design). In addition, the broad pipeline includes five other vaccine candidates currently undergoing clinical trials, targeting Hepatitis C, Tuberculosis, Pneumococcus, as well as Seasonal and Pandemic Influenza.

Intercell's technology platforms include an antigen-discovery system, adjuvants and a novel patch-based delivery system. Based on these technologies, the Company has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Merck & Co., Inc., Wyeth, and Sanofi. Pasteur.

